Matthew D. Galsky

2 weeks ago | urologytimes.com | Matthew D. Galsky |Hannah Clarke

The FDA recently approved perioperative durvalumab (Imfinzi) with neoadjuvant chemotherapy for adult patients with muscle-invasive bladder cancer (MIBC). The approval was supported by data from the phase 3 NIAGARA trial (NCT03732677), which showed that perioperative durvalumab with neoadjuvant chemotherapy significantly extended event-free survival (EFS) and overall survival (OS) vs neoadjuvant chemotherapy alone. In a recent interview with Urology Times®, Matthew D.

Nov 21, 2024 | cell.com | Habib Hamidi |Yasin Senbabaoglu |Niha Beig |Juliette Roels |Cyrus Manuel |Xiangnan Guan | +26 more

Keywordsurothelial carcinomatranscriptomicsmolecular heterogeneityPD-L1 blockadepatient stratificationdigital pathologyGet full text accessLog in, subscribe or purchase for full access. References1. Ishida, Y. ∙ Agata, Y. ∙ Shibahara, K. ... Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell deathEMBO J. 1992; 11:3887-38952. Tang, J. ∙ Yu, J.X. ∙ Hubbard-Lucey, V.M. ...

Sep 18, 2024 | targetedonc.com | Matthew D. Galsky

Matthew Galsky, MD, professor of medicine (hematology and medical oncology), director of genitourinary medical oncology, codirector of the Center of Excellence for Bladder Cancer, and associate director for Translational Research at The Tisch Cancer Institute at Mount Sinai in New York, discusses why some physicians were surprised at the positive outcomes of nivolumab (Opdivo) trials in bladder cancer compared with trials of similar agents.

Sep 15, 2024 | urotoday.com | Matthew D. Galsky

Read the Full Video TranscriptZach Klaassen: Hi, my name is Zach Klaassen. I'm a urologic oncologist at the Georgia Cancer Center in Augusta, Georgia. I'm delighted to be joined today by Dr. Matt Galsky, who is a medical oncologist at the Icahn School of Medicine in Mount Sinai.Matt, thanks very much for joining us today. Matt Galsky: Thank you. Zach Klaassen: So we're discussing your ESMO presentation, looking at RC48G001 Cohort C.

Aug 13, 2024 | targetedonc.com | Matthew D. Galsky

Matthew Galsky, MD, professor of medicine (hematology and medical oncology), director of genitourinary medical oncology, codirector of the Center of Excellence for Bladder Cancer, and associate director for Translational Research at The Tisch Cancer Institute at Mount Sinai in New York, discusses the efficacy of adjuvant nivolumab (Opdivo) in the phase 3 CheckMate 274 trial (NCT02632409).